Injected Molecules Cross Into Brain to Stop Stroke’s Second Attack

The real danger from a stroke often comes after doctors successfully clear the blockage. Blood rushes back into starved tissue, and the brain’s immune system responds with a fury that can kill as many neurons as the initial oxygen loss. Northwestern University researchers have now tested an injectable therapy designed to slip past the body’s toughest barrier and interrupt that destructive cascade.

In mice, a single intravenous dose of engineered peptide assemblies reduced brain damage when given immediately after blood flow was restored. The molecules, which the team calls “dancing molecules” due to their constant motion, crossed the blood-brain barrier and localized in injured tissue without causing toxicity. The findings appeared January 7 in Neurotherapeutics.

Ischemic strokes account for roughly 80 percent of all strokes, and modern medicine has gotten increasingly effective at reopening blocked vessels. What hasn’t advanced is protection against ischemia-reperfusion injury, the wave of inflammation and cell death triggered when oxygen suddenly returns. The Northwestern team used supramolecular therapeutic peptides tuned to remain small enough to circulate, then assemble into larger regenerative structures once inside damaged brain regions.

Small enough to travel, large enough to heal

The researchers tested their approach in a mouse model that mimics real-world stroke care. They blocked blood flow for one hour, restored it, and immediately administered the peptide therapy intravenously. Advanced imaging showed the molecules accumulated preferentially in the ischemic hemisphere, where the blood-brain barrier becomes temporarily more permeable after injury.

Over seven days, treated mice developed significantly smaller infarcts and showed reduced inflammatory markers compared to controls. The team detected no organ damage or immune rejection during that window, suggesting the material is biocompatible enough for eventual human testing.

“Any treatment that facilitates neuronal recovery and minimizes injury would be very powerful, but that holy grail doesn’t yet exist. This study is promising because it’s leading us down a pathway to develop these technologies for this unmet need,” Dr. Ayush Batra explains.

Batra, a neurocritical care physician at Northwestern’s Feinberg School of Medicine, notes that current stroke treatment focuses almost entirely on clearing clots. The peptide platform builds on earlier work showing similar materials could repair damaged spinal cords when injected directly into tissue. Delivering the therapy systemically, without surgery, required dialing down the concentration to prevent clotting while maintaining enough molecular flexibility to penetrate the brain.

Beyond stroke

The treatment works less like a static scaffold and more like an adaptive signal. Molecular motion lets the peptides slip through the blood-brain barrier and engage with cellular receptors involved in survival and repair. That same property could make the approach useful for traumatic brain injury or neurodegenerative diseases like ALS, according to Samuel Stupp, who leads Northwestern’s research in supramolecular materials.

The mice in this study showed no measurable behavioral improvements in the short term, but the reduction in tissue damage suggests the therapy may create conditions for longer-term recovery. Future work will test whether the effect translates into functional gains and whether adding regenerative signals to the peptides could amplify their impact.

For now, the results offer a different way to think about stroke care: not just reopening vessels, but calming the brain’s inflammatory response and helping neurons reconnect after the crisis passes.

Neurotherapeutics: 10.1016/j.neurot.2025.e00820